reports
Rhythm Pharmaceuticals Announces Three Late-breaking Data Abstracts Ac...
Rhythm Pharmaceuticals Announces Three Late-breaking Data Abstracts Accepted for Presentation at ENDO 2025 BOSTON, June 25, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that three late-breaking abstracts have been accepted for presentation at The Endocrine Society’s Annual Meeting (ENDO 2025) taking place July 12-15 in San Francisco, CA. In a live oral presentation, Susan Phillips, M.D., Pediatric Endocrinolog...
Rhythm Pharmaceuticals Inc: 1 director
A director at Rhythm Pharmaceuticals Inc sold/sold after exercising options 3,957 shares at 67.190USD and the significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's d...
Rhythm Pharmaceuticals Announces New Data Presentations on Patients wi...
Rhythm Pharmaceuticals Announces New Data Presentations on Patients with Acquired or Congenital Hypothalamic Obesity (N=35) Treated with Setmelanotide for up to Nine Months in French Early-access Program -- New data showed setmelanotide achieved consistent, meaningful weight reduction -- -- Multiple presentations delivered at the first-ever Joint Congress between the European Society for Paediatric Endocrinology and the European Society of Endocrinology (ESPE-ESE); 32nd annual European Congress on Obesity (ECO); and the 2025 annual meeting of the Pediatric Endocrine Society (PES 2025) -- ...
Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results an...
Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update -- First quarter 2025 net product revenue from global sales of IMCIVREE® (setmelanotide) of $37.7 million -- -- Setmelanotide pivotal Phase 3 TRANSCEND trial met primary endpoint with -19.8% placebo-adjusted BMI reduction in patients (N=120) with acquired hypothalamic obesity -- -- U.S. and EU regulatory submissions for setmelanotide in acquired hypothalamic obesity on track to be completed in the third quarter of 2025 -- -- Topline data from Phase 2 trial of oral MC4R agonist bivamelagon on tr...
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Co...
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that David Meeker, M.D., Chair, President and Chief Executive Officer, will participate in fireside chats at three upcoming investor conferences: Bank of America Securities 2025 Healthcare Conference on Wednesday, May 14, 2025 at 12:20 a.m. ETJefferies Global Healthcare C...
Rhythm Pharmaceuticals to Report First Quarter 2025 Financial Results ...
Rhythm Pharmaceuticals to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025 BOSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, May 7, 2025 to report its first quarter 2025 financial results and provide a corporate update. To access the live conference call, participants may register . While not ...
Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets...
Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120) with Acquired Hypothalamic Obesity -- Patients with acquired hypothalamic obesity on setmelanotide therapy (n=81) achieved mean BMI change of -16.5% compared with +3.3% for placebo (n=39) at 52 weeks (p
Rhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase ...
Rhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide in Patients with Acquired Hypothalamic Obesity Company to host conference call on April 7 at 8 a.m. ET BOSTON, April 06, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the Company will hold a conference call and webcast on Monday, April 7, 2025 at 8:00 a.m. ET to disclose topline results from the Piv...
Rhythm Pharmaceuticals Reacquires Licensing Rights to IMCIVREE® (setme...
Rhythm Pharmaceuticals Reacquires Licensing Rights to IMCIVREE® (setmelanotide) in China with Termination of Agreement with RareStone Ltd. BOSTON, March 20, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it reacquired the rights to IMCIVREE® (setmelanotide) in China, including mainland China, Hong Kong and Macau, as the Company agreed to terminate its 2021 licensing agreement with RareStone Group Ltd. “Rhyt...
Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted to Se...
Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted to Setmelanotide for Treatment of Hypothalamic Obesity in Japan BOSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced it has received orphan drug designation from Japan’s Ministry of Health, Labour and Welfare (MHLW) for setmelanotide as a treatment for acquired hypothalamic obesity. Setmelanotide is a melanocortin-4 receptor (MC4R) agon...
Rhythm Pharmaceuticals and Raymond A. Wood Foundation Announce Researc...
Rhythm Pharmaceuticals and Raymond A. Wood Foundation Announce Research Collaboration New registry study to focus on impact of fatigue in people with craniopharyngioma BOSTON, March 18, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, and the Raymond A. Wood Foundation, a patient advocacy organization for survivors of craniopharyngioma and hypothalamic-pituitary brain tumors, today announced a new research collaboration to study...
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Finan...
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update -- Fourth quarter 2024 net revenue from global sales of IMCIVREE® (setmelanotide) of $41.8 million -- -- On track to report topline data from global Phase 3 trial evaluating setmelanotide in acquired hypothalamic obesity in the second quarter of 2025 -- -- Completed enrollment in the Phase 2 trial of oral MC4R agonist bivamelagon in acquired hypothalamic obesity -- -- FDA approved expanded label for IMCIVREE to include children as young as 2 years old -- -- Ra...
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Fin...
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on Wednesday, February 26, 2025 BOSTON, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, February 26, 2025 to report its fourth quarter and full year 2024 financial results and provide a corporate update. To access the live conference cal...
- Jonathan Moreland
XNCR XENCOR INC.
RLI RLI CORP.
PBF PBF ENERGY INC. CLASS A
ORRF ORRSTOWN FINANCIAL SERVICES INC.
NEOG NEOGEN CORPORATION
MKL MARKEL CORPORATION
LAKE LAKELAND INDUSTRIES INC.
JBLU JETBLUE AIRWAYS CORPORATION
EL ESTEE LAUDER COMPANIES INC. CLASS A
CTSO CYTOSORBENTS
BUSE FIRST BUSEY CORPORATION
BAH BOOZ ALLEN HAMILTON HOLDING CORPORATION CLASS A
CBFV CB FINANCIAL SERVICES INC.
MUR MURPHY OIL CORPORATION
OLN OLIN CORPORATION
WVE WAVE LIFE SCIENCES
OVLY OAK VALLEY BANCORP
FLWS 1-800-FLOWERS.COM CL A
KALV KALVISTA PHARMACEUTICALS
ANAB ANAPTYSBIO INC.
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
MPB MID PENN BANCORP INC.
CIK CREDIT SUISSE ASSET MANAGEMENT INCOME FUND INC.
COGT COGINT
NWFL INC.
FRAF NORWOOD FINANCIAL CORP.
ETST FRANKLIN FINANCIAL SERVICES CO.
LOOP EARTH SCIENCE TECH
ANIX LOOP INDUSTRIES
MFON ANIXA BIOSCIENCES
PNTG MOBIVITY HOLDINGS CORP.
ZYME PENNANT GROUP
PLCE ZYMEWORKS INC.
ALLY THE CHILDREN'S PLACE RETAIL STORES
IMNM INC.
CTOS GMAC LLC
IBRX IMMUNOME
BHRB CUSTOM TRUCK ONE SOURCE
VGAS INC.
TLSI IMMUNITYBIO INC
TKO BURKE & HERBERT BANK & TR/VA
PCSA VERDE CLEAN FUELS INC
PROP TRISALUS LIFE SCIENCES INC
MIO TKO GROUP HOLDINGS
MXF INC.
SUNS PROCESSA PHARMACEUTICALS INC
BATRK PRAIRIE OPERATING CO.
MYCB PIONEER MUN HIGH INCOME OPPORTUNITIES FD INC
THE MEXICO FUND
INC.
SUNRISE REALTY TRUST
LIBERTY MEDIA CORPORATION
MY CITY BUILDERS
INC.
Rhythm Pharmaceuticals to Present at Oppenheimer Annual Healthcare Lif...
Rhythm Pharmaceuticals to Present at Oppenheimer Annual Healthcare Life Sciences Conference in February BOSTON, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that David Meeker, M.D., Chair, President and Chief Executive Officer, will participate in a fireside chat at the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference on Wednesday, February 12, 2025 at 8:40 a.m. ET. The fireside chat wi...
- Jonathan Moreland
RLI RLI CORP.
NEOG NEOGEN CORPORATION
LNDC LANDEC CORP.
LAKE LAKELAND INDUSTRIES INC.
CTSO CYTOSORBENTS
ASA ASA
WVE WAVE LIFE SCIENCES
OVLY OAK VALLEY BANCORP
FLWS 1-800-FLOWERS.COM CL A
FBK FB FINANCIAL CORPORATION
NQP NUVEEN PENNSYLVANIA INVESTMENT QUALITY MUNICIPAL FUND INC.
LW LAMB WESTON HOLDINGS INC.
ANAB ANAPTYSBIO INC.
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
ESQ ESQUIRE FINANCIAL HOLDINGS
MPB MID PENN BANCORP INC.
CIK CREDIT SUISSE ASSET MANAGEMENT INCOME FUND INC.
COGT COGINT
ETST INC.
LOOP EARTH SCIENCE TECH
FUND LOOP INDUSTRIES
ANIX ROYCE FOCUS TRUST
LBSRD INC.
ETON ANIXA BIOSCIENCES
GRX LIBERTY STAR URANIUM & METALS
MFON ETON PHARMACEUTICALS
PNTG THE GABELLI HEALTHCARE & WELLNESSRX TRUST
ZYME MOBIVITY HOLDINGS CORP.
ALLY PENNANT GROUP
ENX ZYMEWORKS INC.
IBRX GMAC LLC
ACXP EATON VANCE NEW YORK MUNICIPAL BOND FUND
CVI IMMUNITYBIO INC
TLSI ACURX PHARMACEUTICALS INC
PCSA CVR ENERGY
PROP INC.
AVDL TRISALUS LIFE SCIENCES INC
MIO PROCESSA PHARMACEUTICALS INC
MXF PRAIRIE OPERATING CO.
SUNS AVADEL PHARMACEUTICALS PUBLIC LIMITED COMPANY
TXO PIONEER MUN HIGH INCOME OPPORTUNITIES FD INC
AMST THE MEXICO FUND
WHLM INC.
IBIO SUNRISE REALTY TRUST
SDHY MORNINGSTAR PARTNERS
BATRK L.P.
MYCB AMESITE INC.
WILHELMINA INTERNATIONAL INC
IBIO INC.
PGIM SHORT DURATION HIGH YIELD OPPORTUNITIES FUND
LIBERTY MEDIA CORPORATION
MY CITY BUILDERS
INC.
- Jonathan Moreland
OPK OPKO HEALTH INC.
NEOG NEOGEN CORPORATION
LNDC LANDEC CORP.
LAKE LAKELAND INDUSTRIES INC.
CTSO CYTOSORBENTS
FRD FRIEDMAN INDUSTRIES INC.
ESQ ESQUIRE FINANCIAL HOLDINGS
MPB MID PENN BANCORP INC.
ETST EARTH SCIENCE TECH
ANIX ANIXA BIOSCIENCES
LBSRD LIBERTY STAR URANIUM & METALS
ALLY GMAC LLC
ACXP ACURX PHARMACEUTICALS INC
GLSI GREENWICH LIFESCIENCES INC
TLSI TRISALUS LIFE SCIENCES INC
PCSA PROCESSA PHARMACEUTICALS INC
MXF THE MEXICO FUND
AMST INC.
MYCB AMESITE INC.
MY CITY BUILDERS
INC.
- Jonathan Moreland
NEOG NEOGEN CORPORATION
LAKE LAKELAND INDUSTRIES INC.
CTSO CYTOSORBENTS
CDXS CODEXIS
ASA ASA
ADC AGREE REALTY CORPORATION
WVE WAVE LIFE SCIENCES
FBK FB FINANCIAL CORPORATION
NQP NUVEEN PENNSYLVANIA INVESTMENT QUALITY MUNICIPAL FUND INC.
LW LAMB WESTON HOLDINGS INC.
ANAB ANAPTYSBIO INC.
DMLP DORCHESTER MINERALS L.P.
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
CIK CREDIT SUISSE ASSET MANAGEMENT INCOME FUND INC.
COGT COGINT
ZIVO INC.
ETST ZIVO BIOSCIENCE
FUND INC.
ANIX EARTH SCIENCE TECH
LBSRD ROYCE FOCUS TRUST
ETON INC.
GRX ANIXA BIOSCIENCES
MCFT LIBERTY STAR URANIUM & METALS
PGNY ETON PHARMACEUTICALS
PNTG THE GABELLI HEALTHCARE & WELLNESSRX TRUST
DCTH MASTERCRAFT BOAT HOLDINGS
ENX PROGYNY
PRLD PENNANT GROUP
NVCT DELCATH SYSTEMS
ANEB EATON VANCE NEW YORK MUNICIPAL BOND FUND
IBRX PRELUDE THERAPEUTICS
BHVN NUVECTIS PHARMA INC
ACXP ANEBULO PHARMACEUTICALS INC
BUKS IMMUNITYBIO INC
GLSI BIOHAVEN LTD
MEGI ACURX PHARMACEUTICALS INC
CVI BUTLER NATIONAL CORP
SRFM GREENWICH LIFESCIENCES INC
OCX MAINSTAY CBRE GBL INFRASTRUCTURE MEGATRENDS FD
AVDL CVR ENERGY
MXF INC.
TXO SURF AIR MOBILITY INC.
TTGT ONCOCYTE CORPORATION
AMST AVADEL PHARMACEUTICALS PUBLIC LIMITED COMPANY
WHLM THE MEXICO FUND
IBIO INC.
SDHY MORNINGSTAR PARTNERS
BATRK L.P.
MYCB TECHTARGET INC.
AMESITE INC.
WILHELMINA INTERNATIONAL INC
IBIO INC.
PGIM SHORT DURATION HIGH YIELD OPPORTUNITIES FUND
LIBERTY MEDIA CORPORATION
MY CITY BUILDERS
INC.
- Jonathan Moreland
OMEX ODYSSEY MARINE EXPLORATION INC.
NEOG NEOGEN CORPORATION
LNDC LANDEC CORP.
CDXS CODEXIS
ASA ASA
NEWT NEWTEK BUSINESS SERVICES INC.
ADC AGREE REALTY CORPORATION
FBK FB FINANCIAL CORPORATION
NQP NUVEEN PENNSYLVANIA INVESTMENT QUALITY MUNICIPAL FUND INC.
LW LAMB WESTON HOLDINGS INC.
ANAB ANAPTYSBIO INC.
DMLP DORCHESTER MINERALS L.P.
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
COGT COGINT
ZIVO INC.
ETST ZIVO BIOSCIENCE
LOVE INC.
FUND EARTH SCIENCE TECH
ANIX LOVESAC
LBSRD ROYCE FOCUS TRUST
ETON INC.
GRX ANIXA BIOSCIENCES
MCFT LIBERTY STAR URANIUM & METALS
PGNY ETON PHARMACEUTICALS
PNTG THE GABELLI HEALTHCARE & WELLNESSRX TRUST
DCTH MASTERCRAFT BOAT HOLDINGS
ENX PROGYNY
PRLD PENNANT GROUP
NOTV DELCATH SYSTEMS
NVCT EATON VANCE NEW YORK MUNICIPAL BOND FUND
ANEB PRELUDE THERAPEUTICS
BHVN INOTIV
ACXP INC.
BUKS NUVECTIS PHARMA INC
GLSI ANEBULO PHARMACEUTICALS INC
MEGI BIOHAVEN LTD
CVI ACURX PHARMACEUTICALS INC
SRFM BUTLER NATIONAL CORP
OCX GREENWICH LIFESCIENCES INC
AVDL MAINSTAY CBRE GBL INFRASTRUCTURE MEGATRENDS FD
TXO CVR ENERGY
MRKR INC.
TTGT SURF AIR MOBILITY INC.
DTIL ONCOCYTE CORPORATION
AMST AVADEL PHARMACEUTICALS PUBLIC LIMITED COMPANY
WHLM MORNINGSTAR PARTNERS
IBIO L.P.
SDHY MARKER THERAPEUTICS INC
TECHTARGET INC.
PRECISION BIOSCIENCES INC.
AMESITE INC.
WILHELMINA INTERNATIONAL INC
IBIO INC.
PGIM SHORT DURATION HIGH YIELD OPPORTUNITIES FUND
- Jonathan Moreland
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.